Abstract
Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Current Pharmaceutical Design
Title: Designer Peptides: Learning from Nature
Volume: 15 Issue: 6
Author(s): A. Shrivastava, A. D. Nunn and M. F. Tweedle
Affiliation:
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Abstract: Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Export Options
About this article
Cite this article as:
Shrivastava A., Nunn D. A. and Tweedle F. M., Designer Peptides: Learning from Nature, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315620
DOI https://dx.doi.org/10.2174/138161209787315620 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science PARP Inhibitors in Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Recent Developments in Taxane Drug Delivery
Current Drug Delivery STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Giant Cell Arteritis - Beyond the Headache
Current Rheumatology Reviews Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets